Page last updated: 2024-12-10

isogentisin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isogentisin: found in plants such as Guttiferae & Gentianaceae.; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

isogentisin : A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1 and 3 and a methoxy group at position 7. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281640
CHEMBL ID4163822
CHEBI ID6017
SCHEMBL ID6907196
MeSH IDM0069310

Synonyms (33)

Synonym
BB 0262113
isogentisin
491-64-5
1,3-dihydroxy--7-methoxyxanthone
1,3-dihydroxy-7-methoxy-9h-xanthen-9-one
ccris 3969
isogentisine
9h-xanthen-9-one, 1,3-dihydroxy-7-methoxy-
xanthen-9-one, 1,3-dihydroxy-7-methoxy-
brn 0258402
1,3-dihydroxy-7-methoxyxanthen-9-one
AKOS004938956
SCHEMBL6907196
unii-jpc53q6qyc
1,3-dihydroxy-7-methoxyxanthone
iso-gentisin
1,3-dihydroxy-7-methoxy-xanthone
jpc53q6qyc ,
STL466246
CHEBI:6017
HMS3468B12
DTXSID00197686
NS-03958
1,3-dihydroxy-7-methoxy-xanthen-9-one
9h-xanthen-9-one, 1,3-dihydroxy-7-methoxy- (9ci)
Q27106981
brn0258402
FT-0777989
mfcd00210570
CHEMBL4163822
CS-0067640
F88002
EN300-302986
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 1.4.3.4 (monoamine oxidase) inhibitorAn EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitor that interferes with the action of monoamine oxidase (EC 1.4.3.4).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
xanthonesAny member of the class of xanthenes based on a xanthone skeleton.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1357472Growth inhibition of human HepG2 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, May-10, Volume: 151Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity.
AID1357474Growth inhibition of human MCF7 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, May-10, Volume: 151Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity.
AID1357473Growth inhibition of human MDA-MB-231 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, May-10, Volume: 151Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (30.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's5 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]